mutLBSgeneDB

mutLBSgeneDB
mutated Ligand Binding Site gene DataBase

Home

Download

 Statistics

Help

About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for PNLIP
Gene summary
Basic gene Info.Gene symbolPNLIP
Gene namepancreatic lipase
SynonymsPL|PNLIPD|PTL
CytomapUCSC genome browser: 10q26.1
Type of geneprotein-coding
RefGenesNM_000936.2,
Descriptionpancreatic triacylglycerol lipasetriacylglycerol acylhydrolase
Modification date20141207
dbXrefs MIM : 246600
HGNC : HGNC
Ensembl : ENSG00000175535
HPRD : 02005
Vega : OTTHUMG00000019103
ProteinUniProt: P16233
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_PNLIP
BioGPS: 5406
PathwayNCI Pathway Interaction Database: PNLIP
KEGG: PNLIP
REACTOME: PNLIP
Pathway Commons: PNLIP
ContextiHOP: PNLIP
ligand binding site mutation search in PubMed: PNLIP
UCL Cancer Institute: PNLIP
Assigned class in mutLBSgeneDBB: This gene belongs to targetable_mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO IDGO TermPubMed ID


Top
Ligand binding site mutations for PNLIP

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
H280L281VBRCA1
H280N279YSKCM1
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.


Top
Protein structure related information for PNLIP
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
H280N279Y0.55757309
H280L281V-1.0958251
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for PNLIP from PDB

Top
Differential gene expression and gene-gene network for PNLIP
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of PNLIP and the right PPI network was created from samples without mutations in the LBS of PNLIP. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Top

Top
Phenotype information for PNLIP
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Top
Pharmacological information for PNLIP
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Gene-centered drug-gene interaction network
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure
Approved|investigationalDB01083OrlistatSmall molecule
ExperimentalDB04233(Hydroxyethyloxy)Tri(Ethyloxy)OctaneSmall molecule
ExperimentalDB08222METHOXYUNDECYLPHOSPHINIC ACIDSmall molecule

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of PNLIP go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS


Top
Conservation information for LBS of PNLIP
Multiple alignments for P16233 in multiple species
LBSAA sequence# speciesSpecies
A195TGLDPAEPCFQ1Homo sapiens
A195TGLDPAEPYFQ1Mus musculus
A195TGLDAAEPYFQ1Rattus norvegicus
D209EEVRLDPTDAQ2Mus musculus, Rattus norvegicus
D209ELVRLDPSDAK1Homo sapiens
D212RLDPTDAQFVD2Mus musculus, Rattus norvegicus
D212RLDPSDAKFVD1Homo sapiens
E204FQGTPEEVRLD2Mus musculus, Rattus norvegicus
E204FQGTPELVRLD1Homo sapiens
F232IPNLGFGMSQT2Mus musculus, Rattus norvegicus
F232VPNLGFGMSQV1Homo sapiens
F94IIIHGFIDKGE2Mus musculus, Rattus norvegicus
F94FIIHGFIDKGE1Homo sapiens
G93RIIIHGFIDKG2Mus musculus, Rattus norvegicus
G93RFIIHGFIDKG1Homo sapiens
H168VHLIGHSLGSH2Mus musculus, Rattus norvegicus
H168VHVIGHSLGAH1Homo sapiens
H280FAACNHLRSYK3Homo sapiens, Mus musculus, Rattus norvegicus
L170VIGHSLGAHAA1Homo sapiens
L170LIGHSLGSHIA1Mus musculus
L170LIGHSLGSHVA1Rattus norvegicus
L205QGTPEEVRLDP2Mus musculus, Rattus norvegicus
L205QGTPELVRLDP1Homo sapiens
L208PEEVRLDPTDA2Mus musculus, Rattus norvegicus
L208PELVRLDPSDA1Homo sapiens
P197LDPAEPCFQGT1Homo sapiens
P197LDPAEPYFQGT1Mus musculus
P197LDAAEPYFQGT1Rattus norvegicus
R207TPEEVRLDPTD2Mus musculus, Rattus norvegicus
R207TPELVRLDPSD1Homo sapiens
S169HVIGHSLGAHA1Homo sapiens
S169HLIGHSLGSHI1Mus musculus
S169HLIGHSLGSHV1Rattus norvegicus


Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas